Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Globalt Udbrugs- og Registerdatabase for Forbedret Bevaring af Donorpankreas (GUARDIAN-PANCREAS)

23. september 2026 opdateret af: Paragonix Technologies

Globalt Udnyttelses- og Registerdatabase for Forbedret Konservering af Donorpancreas (GUARDIAN-PANCREAS)

The primary objective of this study is to collect real-world clinical performance data to assess the clinical outcomes of patients receiving pancreas transplants using donor pancreata transported via the PancreasPak system. These results will be compared to standard of care outcomes, as well as other preservation methods.

Studieoversigt

Detaljeret beskrivelse

GUARDIAN-PANCREAS is a post-market, observational registry of adult transplant recipient patients whose donor pancreas was preserved and transported within the PancreasPak. The data is being collected retrospectively from medical records of patients already transplanted before the initiation of the registry and any new patients who meet the eligibility criteria.

About 1000 subjects meeting the study inclusion and exclusion criteria will be enrolled into the study at about 15 clinical sites.

Candidates that fit the eligibility criteria and have had their donor pancreas transported with a Paragonix product or a standard of care method can be enrolled. The baseline characteristics and outcomes of the two groups will be compared.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

1000

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Patients who have received a pancreas transplant at centers that use the PancreasPak device.

Beskrivelse

Inclusion Criteria:

• Adult or pediatric recipients of pancreas alone, simultaneous pancreas-kidney, or pancreas after kidney transplant

Exclusion Criteria:

  • Donor pancreata that do not meet institutional clinical requirements for transplantation
  • Simultaneous pancreas-kidney transplant recipients who received donor organs from multiple donors

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: RETROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
PancreasPak patient

Patients whose donor pancreas was transported with the PancreasPak device.

The PancreasPak Donor Preservation System is a FDA cleared and CE-marked medical device intended to be used for the static hypothermic preservation of donor pancreata during transportation and eventual transplantation using cold preservation solutions indicated for use in donor pancreata transplantation. The intended organ preservation time for the PancreasPak system is up to 21 hours.

Standard method patients

Patients whose donor pancreas was transported with a method other than the PancreasPak device.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Graft dysfunction
Tidsramme: Post-transplant through 1 year post-transplant

The percentage of subjects in each cohort who experience graft dysfunction post-transplant.

Post-transplant through 1 year post-transplant
Pancreatitis
Tidsramme: Post-transplant through 1 year post-transplant

The percentage of subjects in each cohort who experience pancreatitis post-transplant.

Post-transplant through 1 year post-transplant
Primary Non-Function
Tidsramme: Post-transplant through 7 days post-transplant

The percentage of subjects in each cohort who primary non-function post transplantation.

Post-transplant through 7 days post-transplant
Length of Hospital Stay
Tidsramme: 1 year

How many days the patients stays in the hospital post-transplant.

1 year
Surgical Complications
Tidsramme: Post-transplant through 1 year post-transplant

The percentage of subjects in each cohort who experience surgical complications.

Post-transplant through 1 year post-transplant
Insulin Dependence
Tidsramme: Post-transplant through 1 year post-transplant

The percentage of subjects in each cohort who experience insulin dependence post-transplant.

Post-transplant through 1 year post-transplant
Graft Failure
Tidsramme: Post-transplant through 1 year post

The percentage of subjects in each cohort who develop graft failure post-transplant.

Post-transplant through 1 year post
Survival
Tidsramme: Post-transplant through 1 year post

The percentage of subjects in each cohort who survive through 1 year post-transplant.

Post-transplant through 1 year post

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Length of ICU Stay
Tidsramme: 1 year

How many days the patient stayed in the ICU post-transplant.

1 year
Interventions for Anastomotic Complications
Tidsramme: Post-transplant through 1 year post-transplant

The percentage of subjects in each cohort who required interventions due to anastomotic complications.

Post-transplant through 1 year post-transplant
Intervention for Vascular Complications
Tidsramme: Post-transplant through 1 year-post transplant

The percentage of subjects in each cohort who required interventions due to vascular complications.

Post-transplant through 1 year-post transplant
Medications
Tidsramme: Post-transplant through 1 year post-transplant

The percentage of subjects in each cohort who required the use of various medications.

Post-transplant through 1 year post-transplant

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. januar 2027

Primær færdiggørelse (Anslået)

1. juni 2031

Studieafslutning (Anslået)

1. januar 2032

Datoer for studieregistrering

Først indsendt

17. marts 2026

Først indsendt, der opfyldte QC-kriterier

17. marts 2026

Først opslået (Faktiske)

23. marts 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

28. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

23. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • PGX-008

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner